New Meningitis Case: Not Linked to Kent Outbreak

A suspected case of meningococcal disease has been reported at St John Rigby College. Health authorities have reassured the public that this case is not connected to the recent meningitis B outbreak in Kent, which sadly led to two fatalities. The UK Health Security Agency (UKHSA) has confirmed that close contacts of the affected student have been identified and offered antibiotics as a precautionary measure. The college stated that the risk to students is very low and normal activities can continue. Investigations into the Kent outbreak, which initially saw 23 confirmed cases, have seen numbers decrease to 20 confirmed cases, with a total of 29 cases under investigation. Vaccines and antibiotics have been distributed in Kent, with a significant number of eligible individuals receiving them. The UKHSA indicated that further laboratory assessments may lead to more cases being downgraded. The strain identified in Kent is expected to be covered by the Bexsero vaccine. Family members of one of the deceased victims are advocating for improved access to the meningitis B vaccine for young people. They highlighted that the vaccine, available on the NHS for babies since 2015, is not routinely offered to teenagers and young adults unless paid for privately. This lack of routine provision for older age groups is a key concern for the Meningitis Research Foundation, which is urging the government to reconsider its cost-effectiveness assessments for broader vaccination programs.

The UKHSA and NHS England are continuing to monitor for new cases nationally and are working closely with local authorities. They are encouraging individuals to be aware of the symptoms of invasive meningococcal disease and seek immediate medical attention if they appear. The director of public health for Kent County Council had previously warned of potential sporadic clusters in other parts of the UK as students travel, but emphasized these would be containable. The genetic analysis of the strain in Kent confirms its similarity to strains circulating in the UK for approximately five years, and the Bexsero vaccine is expected to provide protection. The family of Juliette Kenny, one of the victims, has expressed profound grief and is advocating for lasting change to protect young people from meningitis B, emphasizing that such tragedies can be avoided. The Meningitis Research Foundation supports this call, noting that the 2015 decision not to make the vaccine routinely available was based on cost-effectiveness criteria that may not fully account for the severe impact of the disease and the value of prevention.